Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-12-08
DOI
10.2217/fon-2020-0781
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tazemetostat: First Approval
- (2020) Sheridan M. Hoy DRUGS
- The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group
- (2020) Anna Maria Frezza et al. EJSO
- Targeting epigenetics in sarcomas through EZH2 inhibition
- (2020) Antoine Italiano Journal of Hematology & Oncology
- Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
- (2020) Mrinal Gounder et al. LANCET ONCOLOGY
- Immunologic correlates of the abscopal effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 inhibition and radiotherapy
- (2019) Mrinal M. Gounder et al. CLINICAL CANCER RESEARCH
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft
- (2019) Silvia Stacchiotti et al. Cancers
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
- (2019) Birgit Geoerger et al. LANCET ONCOLOGY
- SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma
- (2018) Kenichi Kohashi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy
- (2018) N. Touati et al. CLINICAL ONCOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Thymic involution and rising disease incidence with age
- (2018) Sam Palmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma
- (2018) Anna Maria Frezza et al. JAMA Oncology
- 1892OMolecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)
- (2018) S Daigle et al. ANNALS OF ONCOLOGY
- EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation
- (2018) Weipeng Mu et al. Epigenetics & Chromatin
- EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
- (2017) Dorothy Brach et al. MOLECULAR CANCER THERAPEUTICS
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease
- (2016) Cigall Kadoch et al. BIOCHEMISTRY
- The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study
- (2016) Tomoki Nakamura et al. CANCER
- Epigenetic regulation ofSMARCB1By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas
- (2016) Zoltán Sápi et al. GENES CHROMOSOMES & CANCER
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
- (2016) Ranran Sun et al. Oncotarget
- Prognostic Value of Relevant Clinicopathologic Variables in Epithelioid Sarcoma: A Multi-Institutional Retrospective Study of 44 Patients
- (2015) Naofumi Asano et al. ANNALS OF SURGICAL ONCOLOGY
- SWI/SNF Chromatin Remodeling and Human Malignancies
- (2015) Julien Masliah-Planchon et al. Annual Review of Pathology-Mechanisms of Disease
- The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation
- (2015) Michel DuPage et al. IMMUNITY
- The genomic landscape of epithelioid sarcoma cell lines and tumours
- (2015) Farzad Jamshidi et al. JOURNAL OF PATHOLOGY
- Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
- (2015) Jessamy C. Tiffen et al. Oncotarget
- Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin inp53mutant gastric cancer cells
- (2014) J. Bai et al. CELL PROLIFERATION
- ConsistentSMARCB1homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material
- (2014) Francois Le Loarer et al. GENES CHROMOSOMES & CANCER
- Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
- (2014) Daniel Pink et al. ONCOLOGY
- The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
- (2014) Robert Huether et al. Nature Communications
- SMARCB1expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels
- (2013) Gergő Papp et al. GENES CHROMOSOMES & CANCER
- Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression
- (2013) Kenichi Kohashi et al. MODERN PATHOLOGY
- SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
- (2013) M. Brenca et al. MOLECULAR CANCER THERAPEUTICS
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- Transcriptional regulation by Polycomb group proteins
- (2013) Luciano Di Croce et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)
- (2013) R Ciarapica et al. ONCOGENE
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions
- (2012) Lisa M Sullivan et al. MODERN PATHOLOGY
- Role of Palliative Chemotherapy in Advanced Epithelioid Sarcoma
- (2011) Robin L. Jones et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
- (2010) Boris G. Wilson et al. CANCER CELL
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
- (2010) Gillian L. Dalgliesh et al. NATURE
- Epithelioid Sarcoma
- (2009) Laila Chbani et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Loss of INI1 Expression is Characteristic of Both Conventional and Proximal-type Epithelioid Sarcoma
- (2009) Jason L. Hornick et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic Factors for Survival in Patients with Epithelioid Sarcoma: 441 Cases from the SEER Database
- (2009) Muhammad Umar Jawad et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma
- (2009) Thomas Schmitt et al. Expert Review of Anticancer Therapy
- Epithelioid sarcoma: the University of Washington experience
- (2008) Patrick S. Wolf et al. AMERICAN JOURNAL OF SURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation